Although there are not currently enough data to demonstrate the value of LAG3+ T cells as a predictor of unfavorable responses, ongoing lymphoma clinical trials are targeting LAG3, including in cHL patients [28,44]. This evidence concerns the gene LAG3 and classic Hodgkin lymphoma.